Glaucoma drug BOL-303259-X (Bausch & Lomb) meets endpoints in Phase IIb Study

The Phase IIb study conducted with BOL-303259-X, a novel nitric oxide-donating prostaglandin F2-alpha analog from Bausch & Lomb, in patients with open-angle Glaucoma or Ocular Hypertension, met its primary efficacy endpoint and showed positive results on a number of secondary endpoints. The primary efficacy endpoint was the reduction in mean diurnal intraocular pressure (IOP) on day 28. Two of the four doses tested showed greater IOP reduction compared with Xalatan 0.005%, with the differences reaching more than 1mmHg (statistical significance: p<0.01). the most efficacious dose of bol-303259-x also showed positive results on a number of secondary endpoints including consistently better control of iop over 24 hours on day 28 as well as a statistically significant greater percentage of responders vs. xalatan 0.005 defined as patients achieving an iop of 18mmhg or less. the most common adverse event was ocular hyperemia red eye which occurred at a similar rate across all treatment groups. in light of these results bausch lomb will pay a 10 million milestone payment to drug developer nicox and will initiate a global phase iii development program for bol-303259-x.>